MBX Biosciences Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
63
- Stock Symbol
-
MBX
- Share Price
-
$49.55
- (As of Friday Closing)
MBX Biosciences General Information
Description
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
Contact Information
Website
www.mbxbio.comCorporate Office
- 11711 North Meridian Street
- Suite 300
- Carmel, IN 46032
- United States
Corporate Office
- 11711 North Meridian Street
- Suite 300
- Carmel, IN 46032
- United States
MBX Biosciences Stock Performance
As of 20-Nov-2026, MBX Biosciences’s stock price is $49.55. Its current market cap is $2.46B with 49.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $49.55 | $53.41 | $26.00 - $72.64 | $2.46B | 49.7M | 532K | -$3.07 |
MBX Biosciences Financials Summary
As of 30-Sep-2026, MBX Biosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,407,905 | 1,025,169 | 339,030 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (159,991) | (97,807) | (67,950) | (35,154) |
| Net Income | (145,095) | (86,971) | (61,922) | (32,563) |
| Total Assets | 500,618 | 385,144 | 268,535 | 84,180 |
| Total Debt | 3,291 | 596 | 171 | 324 |
MBX Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MBX Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
MBX Biosciences Comparisons
Industry
Financing
Details
MBX Biosciences Competitors (59)
One of MBX Biosciences’s 59 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Spruce Biosciences | Formerly VC-backed | South San Francisco, CA | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA |
MBX Biosciences Patents
MBX Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024358829-A1 | Pharmaceutical compositions and uses thereof | Pending | 13-Oct-2023 | ||
| EP-4791425-A1 | Pharmaceutical compositions and uses thereof | Pending | 13-Oct-2023 | ||
| WO-2025081012-A1 | Pharmaceutical compositions and uses thereof | Inactive | 13-Oct-2023 | A61P5/18 |
MBX Biosciences Signals
MBX Biosciences ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
MBX Biosciences FAQs
-
When was MBX Biosciences founded?
MBX Biosciences was founded in 2018.
-
Where is MBX Biosciences headquartered?
MBX Biosciences is headquartered in Carmel, IN.
-
What is the size of MBX Biosciences?
MBX Biosciences has 63 total employees.
-
What industry is MBX Biosciences in?
MBX Biosciences’s primary industry is Drug Discovery.
-
Is MBX Biosciences a private or public company?
MBX Biosciences is a Public company.
-
What is MBX Biosciences’s stock symbol?
The ticker symbol for MBX Biosciences is MBX.
-
What is the current stock price of MBX Biosciences?
As of 20-Nov-2026 the stock price of MBX Biosciences is $49.55.
-
What is the current market cap of MBX Biosciences?
The current market capitalization of MBX Biosciences is $2.46B.
-
Who are MBX Biosciences’s competitors?
Adaptimmune Therapeutics, Lisata Therapeutics, Spruce Biosciences, Capricor Therapeutics, and Alzheon are some of the 59 competitors of MBX Biosciences.
-
What is MBX Biosciences’s annual earnings per share (EPS)?
MBX Biosciences’s EPS for 12 months was -$3.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process